Humana (HUM) 10-K Summary — Year Ended Dec 31, 2024
Humana Inc. filed its annual report covering operations through the end of two thousand twenty-four. The filing describes the company's business, risk factors, and financial results for the reported period.
Key takeaway
Year ended Dec 31, 2024 · FY2025 10-K
Humana Inc. filed its annual report covering operations through the end of two thousand twenty-four. The filing describes the company's business, risk factors, and financial results for the reported period.
Financial snapshot
Selected annual figures reported with the filing, shown separately from the narrative summary.
Annual revenue
$117.8B
Revenue reported for the fiscal year.
Operating income
$2.6B
Income from operations reported for the year.
Net income
$1.2B
Net income reported for the year.
Operating cash flow
$3B
Cash generated by operating activities.
Annual revenue trend
Reported annual revenue and its change from the preceding fiscal year.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Dec 31, 2021 | $83.1B | n/a |
| Dec 31, 2022 | $92.9B | +11.8% |
| Dec 31, 2023 | $106.4B | +14.5% |
| Dec 31, 2024 | $117.8B | +10.7% |
Business overview
Humana Inc. operates as a health and well-being company, primarily offering medical and supplemental benefit plans. The company generates revenue through premiums from government-sponsored programs, including Medicare Advantage, and commercial health insurance products.
Financial performance
Revenue increased compared to the prior year, reflecting growth in the company's membership and premium revenue. Operating income and net income both showed profitability for the period, while operating cash flow remained positive.
Material risks
The filing discusses risks related to changes in government healthcare programs, including potential funding cuts or regulatory changes. Other risks include medical cost trends, competition, and the company's reliance on accurate estimation of benefit expenses.
Liquidity and capital
The filing indicates that operating cash flow provided sufficient liquidity for the company's operations during the period. No significant changes to capital allocation strategy were disclosed beyond routine business needs.
What to watch
Readers should monitor whether the company's medical cost ratio remains in line with its expectations in the next filing.